MENU
+Compare
BICX
Stock ticker: OTC
AS OF
Oct 17 closing price
Price
$0.40
Change
-$0.05 (-11.11%)
Capitalization
7.56M

BICX stock forecast, quote, news & analysis

BioCorRx Inc through its subsidiaries, develops and provides treatment programs for substance abuse and related disorders... Show more

BICX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period.
Interact to see
Advertisement
A.I.Advisor
a Summary for BICX with price predictions
Oct 16, 2025

BICX in upward trend: price rose above 50-day moving average on October 03, 2025

BICX moved above its 50-day moving average on October 03, 2025 date and that indicates a change from a downward trend to an upward trend. In of 41 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 14, 2025. You may want to consider a long position or call options on BICX as a result. In of 125 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for BICX just turned positive on October 03, 2025. Looking at past instances where BICX's MACD turned positive, the stock continued to rise in of 60 cases over the following month. The odds of a continued upward trend are .

The 10-day moving average for BICX crossed bullishly above the 50-day moving average on October 14, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a +11 3-day Advance, the price is estimated to grow further. Considering data from situations where BICX advanced for three days, in of 117 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. BICX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (5.890). P/E Ratio (0.000) is within average values for comparable stocks, (115.539). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.345). Dividend Yield (0.000) settles around the average of (0.038) among similar stocks. BICX's P/S Ratio (17.794) is very high in comparison to the industry average of (1.541).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BICX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 85, placing this stock worse than average.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are DaVita (NYSE:DVA), Community Health Systems (NYSE:CYH).

Industry description

Hospital/Nursing Management companies own and operate health care facilities. Their operations include nursing homes, acute care facilities, retirement centers and outpatient surgery centers. HCA Healthcare Inc., Alcon Inc. and Universal Health Services, Inc. are some major companies in this industry. Technology has been at the forefront of development of advanced solutions, including quicker diagnoses of complex conditions. Investments in new diagnostics, healthcare IoT, and other healthcare technologies continue to gather momentum in this industry.

Market Cap

The average market capitalization across the Hospital/Nursing Management Industry is 4.18B. The market cap for tickers in the group ranges from 28.71K to 99.72B. HCA holds the highest valuation in this group at 99.72B. The lowest valued company is MODVQ at 28.71K.

High and low price notable news

The average weekly price growth across all stocks in the Hospital/Nursing Management Industry was 0%. For the same Industry, the average monthly price growth was 3%, and the average quarterly price growth was 14%. RHEPA experienced the highest price growth at 28%, while MODVQ experienced the biggest fall at -65%.

Volume

The average weekly volume growth across all stocks in the Hospital/Nursing Management Industry was -7%. For the same stocks of the Industry, the average monthly volume growth was -41% and the average quarterly volume growth was 22%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 46
P/E Growth Rating: 63
Price Growth Rating: 57
SMR Rating: 100
Profit Risk Rating: 85
Seasonality Score: 14 (-100 ... +100)
View a ticker or compare two or three
BICX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Industry HospitalNursingManagement

Profile
Fundamentals
Details
Industry
N/A
Address
2390 East Orangewood Avenue
Phone
+1 714 462-4880
Employees
11
Web
https://www.biocorrx.com